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4. Supporting tables (S1-S4)
General information for reagents and instrumentation
All solvents and reagents were reagent grade, purchased commercially, and used without further purification unless specified. All chemicals were purchased from Sigma- series LC) on a 50 × 4.6 mm C18 column (XTerra), mobile phase: A, 8.6 mM Et3N/100 mM 1,1,1,3,3,3-hexafluoro-2-propanol in water (pH 8.0); B, methanol. Elution was performed from 100% A isocratic over 10 min followed by a linear gradient of 0 -50% B for 20 min and then 50% B isocratic over another 30 min.
NMR kinetic experiments were performed on a Varian 400 MHz NMR spectrometer (Oxford AS-400) equipped with a Varian 5 mm broadband PFG (z-gradient) probe.
Spectra were collected at 4 °C or 25 °C unless otherwise indicated, and data was analyzed using the Varian VnmrJ 2.1B software. Proton decoupled one-dimensional 31 P spectra (161.8 MHz) were acquired with a spectral width of 5000 Hz, a 90° pulse of 8.5
µs, 256 scans, 2 s repetition delay, and 1.5 s acquisition time for each scan. All 31 P chemical shifts are reported relative to that of phosphate buffer as internal reference (0 ppm at 4 °C). Kinetic studies on the decay of activated monomers were accomplished by real-time 31 P NMR at a given reaction time. The signal intensities of all 31 P spectra are on a uniform arbitrary scale throughout the whole course of the reaction.
LC-MS analysis was performed using an Agilent 6520 Q-TOF mass analyzer and 1200
series HPLC with a Waters XBridge C18 column (3.5 µm, 1x100 mm). Mobile phase A was aqueous 200 mM HFIP and 3 mM TEA at pH 7.0, and mobile phase B was methanol. The HPLC method for 35 µL of a 2.5 µM solution was a linear increase of 5% to 20% B over 30 min at 0.1 mL/min, with the column heated to 60 o C. Sample elution was monitored by absorbance at 260 nm and the eluate was passed directly to an ESI source with 325 °C drying nitrogen gas flowing at 8.0 L/min, a nebulizer pressure of 30 psig and a capillary voltage of 3500 V. Agilent MassHunter Qualitative Analysis software was used for Q-TOF derived MS data.
Synthesis of activated phosphorimidazolide and phosphor-2-methylimidazolide nucleotide monomers
(1) Synthesis of 3'-NH2-7-deaza-ImpddG
The preparation of compound 2 was adapted from a previously reported procedure, (1) with minor modifications as follows.
To a stirred solution of 7-deaza-6-methoxy 2'-deoxy guanosine 1 (1.0 g; 3.57 mmol) in anhydrous pyridine (15 ml) cooled in an ice-bath, trimethylsilyl chloride (1.81 ml; 14.27 mmol) was added slowly. After stirring at room temperature for 45 minutes, isobutyric anhydride (2.22 ml; 14.27 mmol) was added dropwise, and the reaction mixture was stirred under a nitrogen atmosphere at room temperature for 4 h. The reaction mixture was then chilled in an ice-bath, 10 mL of cold water was added and stirred for 30 min.
Concentrated aqueous NH4OH was then added, and stirring for another 30 min. The solvent was removed under high vacuum by rotovaporation to give an oil with salts. The crude product was purified by a silica gel column chromatography using methanol- 351.17, found: 351.1.
To a stirred solution of 2 (1.09 g; 3.11 mmol) and imidazole (508 mg; 7.47 mmol) in anhydrous DMF (15 ml) was added tert-butyldimethyl-silyl chloride (TBDMS-Cl) (563 mg; 3.73 mmol). The reaction mixture was stirred at room temperature for 20 h. Then most solvent was removed under vacuum, and the residue was extracted with CHCl3
(150 ml). The organic layer was washed with saturated aqueous NaHCO3 and NaCl, respectively, and dried over anhydrous Na2SO4. After evaporation of the solvent, the residue was purified by flash column chromatography over silica gel using methanol- 40, 160.80, 149.64, 121.25, 101.75, 99.34, 86.48, 83.40, 72.80, 64.26, 54.51, 41.76, 37.54, 32.57, 27.18, 20.74, 20.77, 19.79, -3.46, -3.58 
The preparation of compound 4 was adapted from a previously reported procedure, (2) with minor modifications as follows.
To a solution of 3 (1.45 g; 3.12 mmol) in anhydrous THF (20 ml) were added 76, 161.51, 161.49, 150.78, 149.89, 149.16, 133.84, 129.59, 122.75, 120.64, 101.71, 99.36, 83.08, 82.17, 73.95, 61.14, 54.48, 40.07, 27.19, 26.94, 20.72, 19.56, -3.51, -3.56 
N-(7-((2R,4R,5R)-5-(((tert-butyldimethylsilyl)oxy)methyl)-4-hydroxytetrahydrofuran-2-yl)-4-methoxy-7H-pyrrolo[2,3-d]pyrimidin-2-yl)isobutyramide (Compound 5).
A suspension of 4 (2.0 g, 3.26 mmol) in methanolic ammonia (20 ml) was stirred for 1 h at room temperature. The resulting homogeneous solution was concentrated under vacuum and the residue was purified by flash column chromatography over silica gel using methanol-chloroform (5%-15%) as the eluent to afford 3 (1.38 g; 91% yield) as a 150.10, 149.44, 127.72, 124.12, 102.52, 98.63, 84.34, 83.00, 71.62, 70.15, 62.54, 54.44, 41.51, 27.12, 23.21, 20.71, 19.64, -3.52, -3.55 
(2R,3R,5R)-2-(((tert-butyldimethylsilyl)oxy)methyl)-5-(2-isobutyramido-4-methoxy-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3-yl methanesulfonate (Compound 6).
To a solution of 5 (970 mg; 2.09 mmol) in anhydrous pyridine (10 ml) were added MsCl (0.41 ml; 597 mg; 5.21 mmol) and DMAP (1.28 g; 10.44 mmol) at room temperature. The reaction mixture was quenched with MeOH after stirring for 15 h and concentrated. The residue was dissolved in CH2Cl2 (100 ml) and washed with water (2×50 ml). The organic layer was dried (Na2SO4), concentrated under vacuum, and the residue was purified by flash column chromatography over silica gel using ethyl acetate-hexane (10%-50%) as the eluent to afford 6 (1.01 g; 89% yield) as a white foam. 1 H NMR δ (400 MHz, CDCl3): 47, 151.25, 149.97, 121.22, 101.49, 100.09, 81.82, 81.62, 79.46, 60.46, 54.45, 40.52, 39.31, 27.05, 20.74, 20.70, 19.63, -3.44, -3.51 
3'-azido-5'-O-(tert-butyldimethylsilyl)-N 2 -isobutyryl-7-deaza-6-methoxy-2',3'-dideoxyguanosine (Compound 7).
To a solution of 6 (840 mg, 1.55 mmol) in anhydrous DMF (12 ml) was added lithium azide (362 mg, 8.04 mmol). The reaction mixture was heated at 90 °C for 2 h. The solvent was evaporated under vacuum, and the residue was extracted with CHCl3 (100 ml). The organic layer was washed with saturated aqueous NaHCO3 and NaCl, respectively, and dried over anhydrous Na2SO4. After evaporation of the solvent, the residue was purified by flash column chromatography over silica gel using ethyl acetate-hexane (10%-60%) as the eluent to afford 7 (606 mg; 80% yield) as a white foam. 1 H NMR δ (400 MHz, CDCl3): 46, 150.78, 149.85, 121.10, 101.74, 99.41, 84.10, 83.34, 63.39, 61.20, 54.42, 38.75, 27.12, 20.70, 19.74, -3.48, -3.62 . ESI-MS calcd for C22H36N7O4Si [(M-H) -]: 488.24, found: 488.1.
3'-azido-5'-O-(tert-butyldimethylsilyl)-N 2 -isobutyryl-7-deaza-2',3'-dideoxyguanosine (Compound 8).
To a solution of 7 (610 mg; 1.25 mmol) in anhydrous DMF (15 ml) was added sodium thiocresolate (1.09 g; 7.46 mmol). The reaction mixture was heated at 90 °C for 1 h. The solvent was evaporated under vacuum, and the residue was extracted with CHCl3 (100 ml). The organic layer was washed with saturated aqueous NaHCO3 and NaCl, respectively, and dried over anhydrous Na2SO4. After evaporation of the solvent, the residue was purified by flash column chromatography over silica gel using ethyl acetate-hexane (10%-50%) as the eluent to afford 8 (569 mg; 96% yield) as a white foam. 
3'-azido-N 2 -isobutyryl-7-deaza-2',3'-dideoxyguanosine (Compound 9).
To a solution of 8 (200 mg; 0.42 mmol) in anhydrous THF (6 ml) was added 1.0 M tetrabutylammonium fluoride (TBAF) in THF solution (0.84 mL; 0.84 mmol). After stirring at room temperature for 2 h, the reaction mixture was concentrated under reduced pressure and partitioned between H2O and CH2Cl2. The organic layer was separated and dried over Na2SO4. After concentration, the residue was purified by flash column chromatography over silica gel using methanol-chloroform (5%-20%) as the eluent to afford 9 (138 mg; 91% yield) as a white foam. 1 H NMR δ (400 MHz, CDCl3): 176. 18, 144.72, 120.80, 106.47, 103.07, 102.94, 87.26, 84.98, 63.61, 62.23, 38.77, 37.55, 30.88, 20.44, 20.34 . ESI-MS calcd for C15H18N7O4 [(M-H) -]: 360.14, found: 360.1.
3'-azido-7-deaza-2',3'-dideoxyguanosine-5'-phosphate (Compound 10).
Compound 9 (120 mg; 0.33 mmol) and proton sponge (86 mg; 0.39 mmol) were dried in a vacuum desiccator over P2O5 overnight before dissolving in trimethyl phosphate (1.0 ml). Then freshly distilled POCl3 (38 µl; 0.39 mmol) was added dropwise at 0°C. After stirring at 0°C for 1.5 h, triethyl ammonium bicarbonate solution (TEAB) (0.1 M; pH 8.0; 1 ml) was added and the mixture was stirred for 10 min at room temperature. Then concentrated NH4OH (5 ml) was added and stirred for 12 h at 60°C. The resulting mixture was concentrated under vacuum and the residue was diluted with 5 ml of water. The crude mixture was then purified by anion exchange chromatography on DEAE-Sephadex A-25 at 4°C using a gradient of TEAB (pH 8.0; 0. 
3'-azido-7-deaza-2',3'-dideoxyguanosine-5'-phosphorimidazolide (Compound 11).
A solution of 10 (156 mg; 0.42 mmol) was co-evaporated with pyridine (10 ml × 3) and then dissolved in anhydrous DMF (3 ml). To the resulting solution, 1,1-carbonyldiimidazole (CDI) (102 mg; 0.63 mmol) was added and the mixture was stirred at room temperature for 5 h. After centrifuging the reaction, the supernatant was treated  Compound 13).
To a solution of 11 (20 mg; 0.04 mmol) in pyridine (1 ml) was added triphenylphosphine 
3'-(9-fluorenylmethoxycarbonyl)-amino-2',3'-dideoxyguanosine-5'-phosphor-2-methylimidazolide (Compound 16b).
General Protocol B:
The following protocol is representative for the conversion of nucleoside 15 to the nucleotides 16a/16b.
Compound 15 (120 mg; 0.24 mmol) and proton sponge (64 mg; 0.29 mmol) were dried in a vacuum desiccator over P2O5 overnight before dissolving in trimethyl phosphate (1.0 ml). Then freshly distilled POCl3 (26 µl; 0.29 mmol) was added dropwise at 0°C. After stirring at 0°C for 1.5 h, 2-methylimidazole (99 mg; 1.2 mmol) (5 equivalents of imidazole was added for Compound 16a) was then added at 0°C. After stirring for an 
3'-amino-2',3'-dideoxyguanosine-5'-phosphor-2-methylimidazolide (3'-NH2-2-MeImpddG, Compound 17b).
General Protocol C: The following protocol is representative for conversion of FMoc protected aminonucleotides 16a/16b to the aminonucleotides 17a/17b.
To a solution of 16b (20 mg; 0.03 mmol) in DMF (0.6 ml) was added piperidine (0.12 ml).
The reaction mixture was stirred at room temperature for 10 min. The resulting mixture was concentrated under vacuum, and the crude product was further purified by reversephase preparative HPLC as previously described to afford 17b. 
(3) Synthesis of 3'-NH2-ImpddC and 3'-NH2-2-MeImpddC
3'-amino-N 4 -benzoyl-2',3'-dideoxycytidine (Compound 19).
To a solution of 3'-amino-N 4 -benzoyl-5'-O-DMTr-2',3'-dideoxycytidine 18 (200 mg; 0.316 mmol) in anhydrous dichloromethane (3 ml) was dropwise added 0.6 ml of 5% dichloroacetic acid at room temperature in two portions. After stirring at room temperature for 20 min, the resulting red reaction mixture was concentrated under reduced pressure and partitioned between H2O and CHCl3. The organic layer was separated and dried over Na2SO4. After concentration, the residue was purified by flash column chromatography over silica gel using methanol-chloroform (2%-10%) as the 
3'-(9-fluorenylmethoxycarbonyl)-amino-N 4 -benzoyl-2',3'-dideoxycytidine (Compound 20).
3'-(9-fluorenylmethoxycarbonyl)-amino-N 4 -benzoyl-2',3'-dideoxycytidine-5'-phosphorimidazolide (Compound 21a).
Compound 20 (120 mg; 0.22 mmol) and proton sponge (70 mg; 0.32 mmol) were dried in a vacuum desiccator over P2O5 overnight before dissolving in trimethyl phosphate (1.0 ml). Then freshly distilled POCl3 (30 µl; 0.32 mmol) was added dropwise at 0°C. After stirring at 0°C for 1.5 h, imidazole (76 mg; 1.12 mmol) (5 equivalents of 2-methylimidazole was added for Compound 21b) was then added at 0°C. After stirring for an additional 4 h at room temperature, TEAB (0.1 M; pH 8.0; 0.5 ml) was added and the mixture was stirred for 10 min at 0°C. Then concentrated NH4OH (5 ml) was added and stirred for 1 h at room temperature. The reaction mixture was partitioned between H2O
and CHCl3. The aqueous layer was lyophilized and the dry crude product was further purified by reverse-phase preparative HPLC as previously described to afford 21a. .
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The procedure for removal of the FMoc group for compounds 22a and 22b is similar to General Protocol C used in preparing compound 17b. 
(4) Synthesis of 3'-NH2-ImpddT and 3'-NH2-2-MeImpddT
3'-azido-3'-deoxythymidine-5'-phosphorimidazolide (Compound 24a).
The preparation procedure for phosphorylation and activation was similar to General Protocol B using in synthesizing compound 16. 
3'-amino-3'-deoxythymidine-5'-phosphorimidazolide (Compound 25a, 3'-NH2-ImpddT).
General Protocol D:
The following protocol is representative for conversion of azidonucleotides 24a/24b to the aminonucleotides 25a/25b, as reported previously, (3) with minor modifications as follows.
To a solution of 24a (28 mg; 0.07 mmol) in ethanol (2 ml) was added saturated aqueous NaHCO3 solution (40 µl). The resulting solution was placed under an argon atmosphere, and Pd/C (2 mg) was added. After the argon was replaced with a hydrogen atmosphere, under the hydrostatic pressure of a 20 cm water column, the slurry was stirred, with the hydrogen atmosphere being replaced every 60 min, until TLC indicated complete conversion (about 6 h). The catalyst was removed by filtration over a bed of celite and washed with ethanol. The combined solutions were concentrated under vacuum, and the crude product was further purified by reverse-phase preparative HPLC as previously described to afford 25a. 1 H NMR δ (400 MHz, D2O): 7.60 (s, 1H), 7.49 (s, 1H), 7.28 (s, 1H), 7.13 (s, 1H), 6.14 (t, J = 6. 
3'-(9-fluorenylmethoxycarbonyl)-amino-2',3'-dideoxyadenosine (Compound 27).
The procedure for selectively protecting the 3'-amino group of compound 27 is similar to General Protocol A using in preparing compound 15. 3'-(9-fluorenylmethoxycarbonyl)-amino-2',3'-dideoxyadenosine-5'-phosphorimdazolide (Compound 28a).
The procedure used for phosphorylation and activation was similar to General Protocol B used in synthesizing compound 16. 
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The procedure for removal of the FMoc group to yield compounds 29a and 29b was similar to General Protocol C using in preparing compound 17b. Figure S1 . 31 P-NMR of 5 mM activated 3'-NH2-ImpddT in a solution of 100 mM HEI, 100 mM MES-CAPS-HEPES, pH 7.5, 150 mM NaCl. Relative intensity t ½ = 26 h Figure S6 . Real-time 31 P-NMR studies of 5 mM activated 3'-NH2-ImpddT over 14 hours at 4 °C.
Supporting Figures
Intensity was monitored at -10.60 ppm. The experiment was performed in a solution of 100 mM HEI, 100 mM MES-CAPS-HEPES, pH 9.3, 150 mM NaCl.
S28
A) B) Figure S7 . Non-enzymatic primer-extension reaction using 3′-NH2-ImpddG (1a) /3′-NH2-7-deaza-ImpddG (1c) as monomers.
(a) Primer-extension reaction scheme showing a 5′-Cy3-labeled 3′-amino-terminated DNA primer annealed to a complementary template. Both 3′-NH2-ImpddG and 3′-NH2-7-deaza-ImpddG monomers participate in a chemical chain reaction extending the primer by four (4) nucleotides on the complementary template forming a chimeric DNA/3'-NP-DNA polymer product. The line in red indicates new phosphoramidate bonds. (b) High-resolution gel electrophoresis analysis of primer-extension products on indicated templates. Primer-extension reactions contained 0.1 µM Cy3-labeled-3′-amino-terminated DNA primer, 0.5 µM template, 100 mM MES-CAPS-HEPES, pH 7.5, and 100 mM 1-(2-hydroxyethyl)imidazole. The reaction was initiated by addition of 5 mM 3′-NH2-ImpddG/3′-NH2-7-deaza-ImpddG. Arrows indicate primer and full-length product.
template Sequence 1 DNA 5' -ACCCCCCAGTCAGTCTACGC-3' Figure S8 . Control experiments on noncomplementary templates. Figure S10 . High-resolution LC-MS profile of the N+5 product resulting from copying a d(C)4 DNA template using 3′-NH2-2-MeImpddG
High resolution MS analysis of the primer-extension products from a reaction of 25 pmol 5′-Cy3-labeled 3′-amino-terminated primer extended on a d(C)4 DNA template for 12 hours followed by ethanol precipitation. Letters in red indicate N3′-P5′ phosphoramidate bonds, and letters underlined in red indicate newly incorporated nucleobases. The monoisotopic mass for the chimeric DNA/3'-NP-DNA of Cy3-labled N+5 product: calculated mass 6776.4013 and observed mass 6776.3741.
6778.3668
Cal: 6776. Figure S11 . EIC a profile of three extension products from copying a d(C)4 DNA template For quantification, the m/z ions (3rd charge state) of all the products were extracted from the TIC b . EIC peaks of m/z 2148.4370 (N+4) and m/z 2257.7932 ions (N+5) were profiled, and both peaked at ~ 30.4 min (retention time). Their relative integrations were compared to obtain relative percentages (Table S1 ).
a EIC: extracted ion chromatogram; b TIC: total ion current.
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Figure S14. High-resolution LC-MS profile of N+3 and N+5 products resulting from copying a d(T)4 DNA template using 3′-NH2-2-MeImpddA High resolution MS analysis of the primer-extension products from a reaction of 30 pmol 5′-Cy3-labeled 3′-amino-terminated primer extended on a d(T)4 RNA template for 12 hours followed by ethanol precipitation. Letters in red indicate N3′-P5′ phosphoramidate bonds, and letters underlined in red indicate newly incorporated nucleobases. Upper panel: the monoisotopic mass for the chimeric DNA/3'-NP-DNA of Tables   Table S1 . High-resolution LC-MS Analysis of primer extension products from copying a d(C)4 DNA template a Relative integrations were obtained as previously described in Figure S11 .
G1
G2 G3 G4 G5 G6 Table S4 . High-resolution MS Analysis of primer extension products from copying a d(T)4 DNA template CGCATCTGACTGAC CTT TTA 5' Cy3--GCGTAGACTGACTGGAA AA NH2 3'
